TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of “Hold” from Brokerages

TScan Therapeutics, Inc. (NASDAQ:TCRX) has received an average recommendation of “Hold” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $6.60.

Several equities analysts have commented on TCRX shares. HC Wainwright lowered their target price on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of TScan Therapeutics in a report on Wednesday, October 8th. Morgan Stanley lowered shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research note on Friday, November 14th. Needham & Company LLC cut their target price on TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 4th. Finally, BTIG Research lowered TScan Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 4th.

Insider Activity at TScan Therapeutics

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp bought 75,500 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The stock was acquired at an average cost of $0.90 per share, with a total value of $67,950.00. Following the completion of the purchase, the insider directly owned 8,012,916 shares in the company, valued at approximately $7,211,624.40. This trade represents a 0.95% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. In the last 90 days, insiders have purchased 161,801 shares of company stock valued at $145,621. 4.35% of the stock is owned by insiders.

Institutional Investors Weigh In On TScan Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of TCRX. Catalyst Funds Management Pty Ltd bought a new stake in shares of TScan Therapeutics during the 2nd quarter worth $26,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of TScan Therapeutics in the 2nd quarter valued at $29,000. Quadrature Capital Ltd acquired a new position in shares of TScan Therapeutics in the 2nd quarter valued at $33,000. Boothbay Fund Management LLC increased its stake in TScan Therapeutics by 50.0% in the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after purchasing an additional 8,121 shares in the last quarter. Finally, Hsbc Holdings PLC acquired a new stake in TScan Therapeutics during the 1st quarter worth about $49,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Stock Performance

Shares of NASDAQ TCRX opened at $1.14 on Wednesday. TScan Therapeutics has a 12-month low of $0.88 and a 12-month high of $3.07. The company has a market cap of $64.70 million, a PE ratio of -1.02 and a beta of 1.04. The stock has a 50 day simple moving average of $1.09 and a 200-day simple moving average of $1.58. The company has a current ratio of 6.44, a quick ratio of 6.44 and a debt-to-equity ratio of 0.23.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.07. The company had revenue of $2.51 million during the quarter, compared to analysts’ expectations of $1.98 million. TScan Therapeutics had a negative return on equity of 73.33% and a negative net margin of 1,692.96%. On average, equities research analysts forecast that TScan Therapeutics will post -1.12 EPS for the current year.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.